Edition:
United States

Merck & Co Inc (MRK)

MRK on New York Consolidated

58.56USD
25 Jul 2016
Change (% chg)

-- (--)
Prev Close
$58.56
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
8,777,435
52-wk High
$60.07
52-wk Low
$45.69

Latest Key Developments (Source: Significant Developments)

Merck names Sanat Chattopadhyay president of Merck Manufacturing Division
Monday, 7 Mar 2016 04:30pm EST 

Merck MRK.N:Names Sanat Chattopadhyay president of Merck Manufacturing Division; will succeed Willie Deese who will retire.Deese will retire on June 1, 2016.Says Chattopadhyay joined Merck in 2009 and currently serves as senior vice president of global Manufacturing Operations.  Full Article

Merck & Co Inc's investigational once-daily formulation of ISENTRESS meets primary and secondary endpoints in pivotal phase 3 study
Monday, 22 Feb 2016 08:00am EST 

Merck & Co Inc:Says its investigational once-daily formulation of ISENTRESS meets primary and secondary endpoints in pivotal phase 3 study.Says 1200 mg raltegravir was statistically non-inferior to the marketed formulation approved dose.  Full Article

Merck & Co Inc gives FY 2016 guidance
Wednesday, 3 Feb 2016 06:45am EST 

Merck & Co Inc:Expects FY 2016 GAAP EPS to be between $1.96 and $2.23.Expects FY 2016 expects non-GAAP EPS to be between $3.60 and $3.75, Including an about 4 Percent negative Impact from foreign exchange.Anticipates FY 2016 worldwide sales to be between $38.7 billion and $40.2 billion, Including an about 3 percent negative impact from foreign exchange.  Full Article

Merck announces FDA acceptance of Biologics License Application for Bezlotoxumab
Wednesday, 27 Jan 2016 08:30am EST 

Merck & Co Inc:Announces FDA Acceptance of Biologics License Application for Bezlotoxumab, an Investigational Antitoxin for Prevention of Clostridium Difficile Infection Recurrence.Says the FDA granted Priority Review for bezlotoxumab, with a Prescription Drug User Fee Act (PDUFA) action date of July 23, 2016.Company also has filed a marketing authorization application for bezlotoxumab with the European Medicines Agency (EMA) that is currently under review.  Full Article

Merck & Co Inc acquires IOmet Pharma
Monday, 11 Jan 2016 04:08pm EST 

Merck & Co Inc:Has acquired IOmet.Under terms of the agreement, Merck, through a subsidiary, will acquire IOmet, including its comprehensive pre-clinical pipeline of IDO (indoleamine-2,3-dioxygenase 1), TDO (tryptophan-2,3-dioxygenase), and dual-acting IDO/TDO inhibitors.Based on the transaction, IOmet will become a wholly owned subsidiary of Merck.Financial terms of the acquisition were not disclosed.  Full Article

Biocartis Group announces collaboration with Merck
Thursday, 7 Jan 2016 02:00am EST 

Biocartis group NV:Biocartis and Merck to collaborate on new liquid biopsy technology for ras biomarker testing.  Full Article

Merck & Co Inc says FDA approves expanded age indication for Gardasil 9 in males
Tuesday, 15 Dec 2015 05:07pm EST 

Merck & Co Inc:Says FDA approved Gardasil 9 for males 16 through 26 years of age for the prevention of anal cancers and genital warts caused by nine HPV types.  Full Article

Merck & Co Inc - FDA panel rejects Merck claim Zetia/Vytorin cut heart risk - Reuters
Monday, 14 Dec 2015 04:28pm EST 

Merck & Co Inc:Merck & Co should not be allowed to claim that its cholesterol-lowering drugs Zetia and Vytorin reduce the risk of heart attacks and strokes in patients with coronary heart disease, an advisory committee to the U.S. Food and Drug Administration concluded on Monday - RTRS.  Full Article

Amgen And Merck Announce Cancer Immunotherapy Collaboration For Patients With Non-Hodgkin Lymphoma
Friday, 4 Dec 2015 08:01am EST 

Amgen and Merck:Says cancer immunotherapy collaboration to support a Phase 1b/3 study investigating BLINCYTO®(blinatumomab) in combination with KEYTRUDA(pembrolizumab) in patients with diffuse large B-cell lymphoma (DLBCL).which is the most common type of non-Hodgkin lymphoma (NHL).BLINCYTO is Amgen's CD19 bispecific T cell engager (BiTE, and KEYTRUDA is Merck's anti-PD-1 therapy.study is an open-label, multicenter, randomized trial to evaluate safety and efficacy in patients with DLBCL.companies also announced a second immunotherapy cancer collaboration to support a Phase 1/2 study of AMG 820, Amgen's anti-colony-stimulating factor 1 receptor (CSF1R) antibody, in combination with KEYTRUDA in patients with select advanced solid tumors.open-label study is designed to evaluate safety and efficacy in patients with select advanced solid tumors, including non-small cell lung, colorectal and pancreatic cancers.  Full Article

Merck & Co Inc announces increased quarterly dividend
Tuesday, 24 Nov 2015 12:35pm EST 

Merck & Co Inc:Announces increased quarterly dividend.Sets quarterly dividend of $0.46 per share.Says increased the company's quarterly dividend to $0.46 per outstanding share of the company's common stock, up $0.01.Says payment will be made on January 8, 2016, to stockholders of record at the close of business on Dec. 15.  Full Article

BRIEF-Enigma biomedical announces research collaboration agreement with Biogen Inc and Merck

* Collaboration focused on qualification and validation of Tau imaging agent developed by Merck, MK-6240